Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tocladesine

An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a purine analogue and competes with ATP in transcription. In addition, generation of 8-chloro-ATP depletes the endogenous ATP pool that is essential for many biological reactions in intracellular energy transfer. As a result, this agent causes RNA synthesis inhibition, blocks cellular proliferation, and induces apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:8-chloro cyclic AMP
adenazole
cAMP
ICN-1256
Abbreviation:8-Cl-cAMP
c-AMP
cAMP
Chemical structure:8-chloro-cyclic adnenosine monophosphate
8-chloroadenosine 3',5' monophosphate
8-chloroadenosine cyclic 3':5'-monophosphate
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search